Burns L J, Westberg M W, Burns C P, Klassen L W, Goeken N E, Ray T L, Macfarlane D E
Acta Haematol. 1984;71(4):270-6. doi: 10.1159/000206599.
2 fatal cases of graft-versus-host disease (GvHD) occurred following blood product transfusions given to patients receiving standard chemotherapy for Hodgkin's disease. GvHD was established by HLA typing, clinical course, and compatible skin biopsy. 23 cases of GvHD following transfusion of blood products from normal donors are also reviewed. It should be suspected when fever or rash appear 1-2 weeks after transfusion of unirradiated blood products into a compromised host or when pancytopenia following chemotherapy is prolonged or unexpectedly severe. Prevention of GvHD by irradiation of granulocytes, platelets and packed red blood cells given to immunosuppressed patients is recommended to prevent this often fatal disease.
2例霍奇金病患者在接受标准化疗时输注血液制品后发生了移植物抗宿主病（GvHD）致死病例。通过HLA分型、临床病程及相符的皮肤活检确诊为GvHD。本文还回顾了23例输注正常供者血液制品后发生GvHD的病例。当未照射的血液制品输注给免疫功能低下的宿主后1-2周出现发热或皮疹，或化疗后全血细胞减少持续时间延长或异常严重时，应怀疑发生了GvHD。建议对免疫抑制患者输注的粒细胞、血小板和浓缩红细胞进行照射，以预防GvHD，防止这种常致命的疾病发生。
